ALK inhibitor therapy achieved
“remarkable” response rates
in a small study of patients
with ALK-positive adult-onset neuroblastoma. Some patients who did not respond to initial treatment with 1 ALK inhibitor had a subsequent response to lorlatinib (Lorbrena), which had the best showing among
ALK inhibitors evaluated in this
setting. The results of this retrospective study were presented at the American Society of Clinical Oncology
2021 virtual annual meeting. Read More ›
